- Home
- ICCM vs VRCA Comparison
ICCM vs VRCA Comparison
Compare ICCM & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICCM | VRCA |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.5M | 32.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | ICCM | VRCA |
|---|---|---|
| Price | $0.69 | $8.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | 374.9K | ★ 387.1K |
| Earning Date | 11-19-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,975,000.00 | ★ $30,829,000.00 |
| Revenue This Year | $13.67 | $373.65 |
| Revenue Next Year | $38.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $0.59 | $3.28 |
| 52 Week High | $1.66 | $10.50 |
Technical Indicators
Market Signals| Indicator | ICCM | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 43.70 | 66.24 |
| Support Level | $0.67 | $6.26 |
| Resistance Level | $0.73 | $9.78 |
| Average True Range (ATR) | 0.04 | 1.16 |
| MACD | 0.01 | 0.30 |
| Stochastic Oscillator | 65.56 | 74.02 |
Price Performance
Historical ComparisonAbout ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.